U.S. Heparin Market Analysis

U.S. Heparin Market Analysis

The low molecular weight heparin market valuation in the U.S. was more than USD 535.4 million in 2019. Low molecular weight heparin are heterogenous compounds and have distinct biochemical and pharmacological properties. Low molecular weight heparin produces a more predictable anticoagulant response, has longer shelf-life and does not require frequent monitoring. Such properties and various applications associated with low molecular weight heparin will increase the adoption rate. Additionally, increasing demand in various healthcare settings owing to growing burden of cardiovascular and chronic diseases will boost the market revenue.   
 

The venous thromboembolism segment size was over USD 328 million in 2019 and is expected to show lucrative growth of 6.8% during the forecast period. Growing rate of chronic diseases including venous thromboembolism will serve as a major factor responsible for the U.S. heparin market growth. For instance, as per the Centers for Disease Control & Prevention (CDC) estimates, about 900,000 people are affected annually by thromboembolism in the U.S. This implicates that there will be a constant increase in the number of patients requiring heparin for treatment of venous thromboembolism. Such high number of chronic conditions will lead to an increased demand for heparin injections for treatment.
 

Hospital pharmacy segment in the U.S. accounted for 54.3% heparin market share in 2019. Patients tend to prefer hospitals more as compared to other healthcare settings as they offer high quality care and ease of availability of medicines. Hospital pharmacies mainly stock and monitor the supply of larger range of medications that are used in the hospital. Furthermore, constant availability and supply of specialized and life-saving medications will supplement the segment growth.